Zentek (CVE:ZEN) Share Price Crosses Below Two Hundred Day Moving Average - Should You Sell?

Key Points

• Zentek's share price crossed below its 200-day moving average, trading as low as C$0.64 and last at C$0.65 on volume of 33,388 shares; the 200-day MA is C$0.96 and the 50-day MA is C$0.78.
• The company has a market cap of C$69.90 million, a high debt-to-equity ratio of 15.41, a current ratio of 1.00 and quick ratio of 7.59, with a negative P/E of -8.13 and a beta of 0.36.
• Zentek conducts R&D in graphene and related nanomaterials—producing graphene-based antimicrobial coatings, PPE, HVAC filters, rapid diagnostics and pharma products—and owns the Albany graphite project in Northern Ontario.

Zentek Ltd. (CVE:ZEN - )'s share price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of C$0.96 and traded as low as C$0.64. Zentek shares last traded at C$0.65, with a volume of 33,388 shares.

Zentek Trading Down 4.4%

The company has a debt-to-equity ratio of 15.41, a current ratio of 1.00 and a quick ratio of 7.59. The company has a market cap of C$69.90 million, a price-to-earnings ratio of -8.13 and a beta of 0.36. The business has a 50 day simple moving average of C$0.78 and a 200 day simple moving average of C$0.96.

About Zentek

Zentek Ltd., together with its subsidiaries, engages in the research and development of graphene and related nanomaterials in Canada. The company develops graphene-based antimicrobial coating under the ZenGUARD brand, surgical masks, HVAC filters, personal protective equipment, rapid detection point of care diagnostics tests, and pharmaceutical products based on graphene-based compounds. It is also developing graphene oxide synthesis and graphene synthesis. In addition, the company owns 100% interest in the Albany graphite project located in Northern Ontario, Canada.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.